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Objective. To evaluate the effect of golimumab on physical function, health-related quality of life (HRQOL), and
productivity in psoriatic arthritis (PsA).
Methods. GO-REVEAL was a multicenter, randomized, placebo-controlled study. Adult patients with active PsA (n 
405) received golimumab (50 or 100 mg) or placebo every 4 weeks, with early escape at week 16 (placebo 3 50 mg, 50
3 100 mg) or placebo crossover to golimumab 50 mg at week 24. Patient-reported outcomes included physical function
(Health Assessment Questionnaire [HAQ] disability index [DI] score), HRQOL (36-item Short Form health survey [SF-36]
mental component summary [MCS] and physical component summary [PCS] scores), and productivity (home/school/
work). Clinical response was assessed using the 28-joint Disease Activity Score using the C-reactive protein level
(DAS28-CRP) and the Psoriasis Area and Severity Index (PASI) score for arthritis and skin symptoms, respectively.
Results. At week 24, golimumab-treated patients had signiﬁcant mean improvements in HAQ DI (0.36), SF-36 (PCS 7.83,
MCS 3.84), and productivity (2.24) scores compared with placebo (0.01, 0.67, 0.60, and 0.08, respectively; P < 0.001
for all). Also, greater proportions of golimumab- than placebo-treated patients had clinically meaningful improvements
in HAQ DI (>0.30) and SF-36 PCS and MCS (>5) scores at week 24 (P < 0.05). Also at week 24, improvements in
DAS28-CRP scores were signiﬁcantly but moderately correlated with improvements in HAQ DI, SF-36 PCS, and produc-
tivity scores. Correlations between these patient-reported outcomes and improvements in PASI, enthesitis, and dactylitis
scores were very weak. Improvements in HAQ DI, SF-36, and productivity scores were similar among all groups by week
52 and week 104 when including placebo 3 golimumab crossover patients.
Conclusion. Golimumab-treated patients had signiﬁcant improvements in physical function, HRQOL, and productivity
through week 24; these improvements correlated with clinical improvement in signs and symptoms of peripheral arthritis
and were sustained through 2 years.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, debilitating, inﬂam-
matory immune-mediated disease of the skin and joints.
Patients with PsA may experience signiﬁcant disability
resulting from emotional distress associated with psoriatic
skin lesions, as well as arthritis-related joint pain and
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physical limitations (1). Patients with PsA have exhibited
degrees of impaired physical function and health-related
quality of life (HRQOL) similar to patients with rheuma-
toid arthritis (RA) (2,3). Patients with PsA, who tend to be
younger and are more commonly male, also have con-
straints on productivity similar to or worse than those
observed in patients with RA (2–6).
Previous evaluations of tumor necrosis factor  (TNF)
antagonists have demonstrated the effectiveness of these
agents in ameliorating disease burden (7). In a recent re-
view of relevant head-to-head clinical trials comparing
either adalimumab, etanercept, golimumab, or inﬂiximab
with placebo, these agents were determined to provide
similar improvements in functional capacity and HRQOL.
These treatment effects generally reached levels deﬁned as
minimum clinically important differences (8,9).
Golimumab is a human anti-TNF monoclonal antibody
that binds with high afﬁnity and speciﬁcity to soluble and
transmembrane TNF and has demonstrated efﬁcacy in RA
(10), PsA (11), and ankylosing spondylitis (12). We previ-
ously reported on the efﬁcacy and safety of golimumab in
patients with PsA through week 104 of the GO-REVEAL
trial, a phase III, multicenter, randomized, double-blind,
placebo-controlled trial, the results of which indicated
that subcutaneously administered golimumab therapy (50
or 100 mg every 4 weeks) yielded signiﬁcant and sustained
improvements in the signs and symptoms of active PsA,
including associated skin disease (11,13,14). Here we re-
port ﬁndings related to patient HRQOL and productivity
through week 104 of the GO-REVEAL trial.
PATIENTS AND METHODS
Patients. Patient eligibility criteria for the GO-REVEAL
trial have been previously detailed (11). Brieﬂy, eligible
patients had active PsA despite therapy with disease-mod-
ifying antiinﬂammatory drugs or nonsteroidal antiinﬂam-
matory drugs (NSAIDs). Active PsA was deﬁned as 3
swollen and 3 tender joints and a qualifying plaque
psoriasis lesion, i.e., 2 cm in diameter. Previous use of
anti-TNF agents, rituximab, natalizumab, or cytotoxic
agents was prohibited. Continuation of stable doses of
methotrexate, NSAIDs, and/or corticosteroids (prednisone
10 mg/day) was permitted. Institutional review board or
ethics committee approval and patient written informed
consent were obtained prior to the study procedures.
Study design. The study design of this phase III, multi-
center, double-blind, placebo-controlled trial has been
reported previously (11). Brieﬂy, 405 patients were ran-
domized to receive subcutaneous injections of placebo,
golimumab 50 mg, or golimumab 100 mg at baseline and
every 4 weeks thereafter. Randomization was stratiﬁed by
investigational site and baseline methotrexate use (yes/
no). At week 16, patients with 10% improvement from
baseline in both swollen and tender joint counts entered
blinded early escape, with dose adjustment from placebo
to golimumab 50 mg or from golimumab 50 mg to 100 mg.
Patients in the golimumab 100 mg group who met the early
escape criteria continued with blinded golimumab 100
mg. At week 24, all patients in the placebo group who were
still receiving placebo crossed over to golimumab 50 mg.
After the week 52 database lock, one-time golimumab dose
adjustments (503100 mg or 100350 mg) were permitted
at the investigator’s discretion.
Study end points. Physical function was assessed using
the Health Assessment Questionnaire (HAQ) disability in-
dex (DI) (15), with clinically meaningful change deﬁned as
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Signiﬁcance & Innovations
● Six months of golimumab therapy yielded signiﬁ-
cant and clinically meaningful improvements in
physical function, health-related quality of life,
and productivity in patients with active psoriatic
arthritis (PsA) despite conventional therapy.
● In golimumab-treated PsA patients, improvements
in physical function, health-related quality of life,
and productivity at week 24 were signiﬁcantly but
moderately correlated with improvements in dis-
ease activity as assessed by the 28-joint Disease
Activity Score; improvements were maintained
through 2 years of golimumab therapy.
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a decrease (improvement) of 0.30 (16,17). HRQOL was
assessed using the physical component summary (PCS)
and mental component summary (MCS) scores of the 36-
item Short Form health survey (SF-36) (18). In post hoc
analyses of these quality of life variables, a clinically
meaningful change was deﬁned as an improvement of 5
points (19). The impact of PsA on daily productivity at
work, school, or home in the previous 4 weeks was self-
reported on a visual analog scale (VAS) ranging from 0–10
cm, where 0  productivity not affected at all and 10 
productivity affected very much.
Among patients with 3% of body surface area with
psoriasis skin involvement at baseline, response of psori-
asis symptoms was assessed using 75% improvement
in Psoriasis Area and Severity Index (PASI75) (20) re-
sponse criteria. Arthritis disease activity was assessed us-
ing the American College of Rheumatology criteria for
20% improvement (ACR20) (21) and also with the 28-
joint Disease Activity Score using the C-reactive protein
level (DAS28-CRP) (22). In post hoc analyses, the propor-
tions of patients with a DAS28-CRP score 2.6 were de-
termined (23).
Dactylitis was scored in each of 20 ﬁngers and toes from
0–3, where 0  no dactylitis and 3  severe dactylitis
(range 0–60). Entheseal tenderness was scored for 15 sites
(where 0  absent and 1  present, range 0–15) using the
PsA-modiﬁed (left and right insertion of plantar fascia
added) Maastricht Ankylosing Spondylitis Enthesitis
Score (24). For both enthesitis and dactylitis, a score 1
denoted presence.
Statistical methods. As prespeciﬁed in the study ana-
lytical plan, treatment group differences at weeks 16 and
24 were assessed with a 2-sided analysis of variance on the
van der Waerden normal scores test for continuous vari-
ables or the Cochran-Mantel-Haenszel test for categorical
variables. All tests were conducted with patients’ baseline
methotrexate usage (yes/no) as a factor in the model and
at a signiﬁcance level of 0.05. Week 16 and week 24 data
were analyzed using the intent-to-treat method, so that
analyses were based on randomized treatment. Although
patients who discontinued treatment were encouraged to
return for scheduled visits, any missing data were replaced
using the last observation carried forward (LOCF) method.
For patients in the placebo or golimumab 50 mg group who
entered early escape, the last observation before their dose
adjustment at week 16 was used for week 24 analyses
(LOCF method). Patients in the 100 mg group were not
eligible to receive a dose adjustment according to the pro-
tocol; therefore, no adjustment of week 24 data was made
for patients who met the early escape criteria. For all week
52 and week 104 analyses, a completer analysis utilizing
observed data was employed.
In post hoc analyses, Spearman’s correlation analysis
was performed to evaluate the relationships between im-
provements from baseline to week 24 in DAS28-CRP, en-
thesitis, dactylitis, and PASI scores and improvements
from baseline to week 24 in HAQ DI score, SF-36 PCS and
MCS scores, and the impact of disease on productivity.
Also, the proportion of patients with normal HAQ DI
(0.5) and SF-36 PCS (50) and MCS (50) scores and the
percent improvement in the impact of disease on produc-
tivity at both weeks 52 and 104 were summarized, with
patients stratiﬁed by achievement (or not) of a DAS28-CRP
score 2.6. Odds ratios (ORs) for patients achieving nor-
mal HAQ DI or SF-36 summary scores among patients who
achieved the DAS28-CRP criterion were estimated using
logistic regression models that were adjusted for age, sex,
and baseline HAQ DI or SF-36 summary scores.










Men, no. (%) 69 (61) 89 (61) 86 (59) 175 (60)
White, no. (%) 110 (97) 141 (97) 142 (97) 283 (97)
Age, years 47.0  10.6 45.7  10.7 48.2  10.9 47.0  10.9
PsA duration, years 7.6  7.9 7.2  6.8 7.7  7.8 7.5  7.3
No. of swollen joints (range 0–66) 13.4  9.8 14.1  11.4 12.0  8.5 13.0  10.1
No. of tender joints (range 0–68) 21.9  14.7 24.0  17.1 22.5  15.7 23.3  16.4
CRP level, mg/dl 1.3  1.6 1.3  1.6 1.4  1.8 1.3  1.7
HAQ DI score (range 0–3) 1.03  0.55 0.98  0.65 1.05  0.62 1.02  0.64
SF-36 PCS score (range 0–100) 31.9  9.3 33.0  10.7 32.8  8.9 32.9  9.8
SF-36 MCS score (range 0–100) 47.6  10.7 45.4  12.2 45.0  11.7 45.2  12.0
DAS28-CRP score 4.9  1.0 5.0  1.1 4.9  1.1 4.9  1.1
PASI score (range 0–72)† 8.4  7.4 9.8  8.6 11.1  9.5 10.4  9.1
Patients with ﬁngers/toes with dactylitis, no. (%) 38 (34) 50 (34) 49 (34) 99 (34)
Patients with enthesitis, no. (%)‡ 88 (78) 109 (75) 115 (79) 224 (77)
Productivity score (0–10-cm VAS) 5.3  2.8 5.2  2.9 5.6  2.6 5.4  2.8
* Values are the mean SD unless otherwise indicated. PsA psoriatic arthritis; CRP C-reactive protein; HAQ Health Assessment Questionnaire;
DI  disability index; SF-36  36-item Short Form health survey; PCS  physical component summary; MCS  mental component summary;
DAS28-CRP  28-joint Disease Activity Score using the CRP level; PASI  Psoriasis Area and Severity Index; VAS  visual analog scale.
† In patients with 3% of body surface area with psoriasis skin involvement.
‡ As determined using the PSA-modiﬁed Maastricht Ankylosing Spondylitis Enthesitis Score index.
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RESULTS
Patient disposition and characteristics at baseline.
Four hundred ﬁve patients were randomized and received
the study agent; 25 patients discontinued treatment
through week 24 (11), 47 discontinued through week 52
(13), and 70 discontinued through week 104 (14). Baseline
characteristics indicated active disease (mean DAS28-CRP
scores of 4.9–5.0 and mean CRP levels of 1.3–1.4 mg/dl)
and a moderate impact of disease on productivity (mean
scores of 5.2–5.6 on a 10-cm VAS). No relevant differences
in baseline patient characteristics were observed among
the randomized treatment groups (Table 1).
Physical function, HRQOL, and productivity through
week 24. Mean SD improvements from baseline to week
14 in the HAQ DI score were signiﬁcantly greater in the
golimumab 50 mg (0.31  0.50) and 100 mg (0.38  0.51)
groups when compared with the placebo group (0.04 
0.44; P  0.001 for both comparisons), and these differ-
ences were maintained at week 24 (Table 2). Similarly,
improvements in SF-36 PCS and MCS scores at weeks 14
and 24 were signiﬁcantly greater in both golimumab
groups than in the placebo group (Table 2). Additionally,
signiﬁcantly greater proportions of patients in the goli-
mumab groups achieved clinically meaningful improve-
ments in HAQ DI and SF-36 PCS scores at weeks 14 and 24
(Figure 1).
The impact of disease on productivity was also signiﬁ-
cantly decreased in both the golimumab 50 and 100 mg
groups versus the placebo group at weeks 16 and 24 (Table
2). Among all patients who received golimumab, the
mean  SD impact of disease on productivity lessened by
2 points, while there was little change from baseline in
the placebo group at both week 16 (2.06  2.90 versus
0.01  2.56; P  0.001) and week 24 (2.24  2.89 versus
0.08  2.62; P  0.001) (Table 2).
Among all patients, improvements from baseline to
week 24 in DAS28-CRP scores were signiﬁcantly and mod-
erately correlated with improvements in HAQ DI and
SF-36 PCS scores and the impact of disease on productiv-
ity. In addition, patients with more severe disease at base-
line, as assessed by DAS28-CRP or PASI scores, demon-
strated greater improvement in these patient-reported
outcomes. Improvement in enthesitis and dactylitis also
correlated with improvements in HAQ DI and SF-36 PCS
scores, as well as with improvements in the impact of
disease on productivity. In all cases, however, the corre-
Table 2. Improvements from baseline to weeks 14, 24, 52, and 104 in physical function,











Week 14 0.04  0.44 0.31  0.50† 0.38  0.51† 0.35  0.50†
Week 24‡ 0.01  0.49 0.33  0.55† 0.39  0.50† 0.36  0.53†
Week 52§ 0.37  0.56 0.41  0.53 0.43  0.53 0.42  0.53
Week 104§ 0.36  0.58 0.43  0.56 0.45  0.55 0.44  0.55
SF-36 PCS score
Week 14 0.63  7.68 6.53  8.88† 7.85  9.55† 7.19  9.23†
Week 24‡ 0.67  8.72 7.42  9.17† 8.22  9.64† 7.83  9.41†
Week 52§ 8.25  10.50 9.87  9.51 9.19  10.29 9.53  9.90
Week 104§ 8.76  11.41 8.70  9.56 8.50  10.45 8.60  10.00
SF-36 MCS score
Week 14 0.40  11.39 2.79  10.27¶ 3.56  12.06¶ 3.18  11.20¶
Week 24‡ 0.60  12.13 3.37  10.55# 4.29  11.03# 3.84  10.79†
Week 52§ 3.69  11.23 3.95  11.73 4.84  11.60 4.40  11.65
Week 104§ 2.99  11.08 4.71  11.35 4.69  12.21 4.70  11.77
Impact of disease on
productivity
Week 16‡ 0.01  2.56 1.69  2.77† 2.43  2.98† 2.06  2.90†
Week 24‡ 0.08  2.62 1.86  2.74† 2.63  2.99† 2.24  2.89†
Week 52§ 2.81  3.23 2.58  2.65 2.88  3.06 2.74  2.87
Week 104§ 2.80  3.20 2.50  2.83 3.12  3.11 2.82  2.99
* Values are the mean  SD. HAQ  Health Assessment Questionnaire; DI  disability index; SF-36  36-item Short
Form health survey; PCS  physical component summary; MCS  mental component summary.
† P  0.001 vs. placebo.
‡ Week 16 and week 24 data were analyzed using the intent-to-treat method; the last observation carried forward method
was employed to impute missing data. For patients in the placebo or golimumab 50 mg group who entered early escape,
the last observation before their dose adjustment at week 16 was used for week 24 analyses. Patients in the 100 mg group
were not eligible to receive a dose adjustment according to the protocol; therefore, no adjustment of week 24 data was
made for patients who met the early escape criteria.
§ For all week 52 and week 104 analyses, a completer analysis utilizing observed data was employed.
¶ P  0.05 vs. placebo.
# P  0.01 vs. placebo.
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lations were relatively weak, with correlation coefﬁcients
0.3 (data not shown).
Overall, patients achieving an ACR20 and/or PASI75
response had greater improvement in productivity and the
SF-36 PCS and MCS scores versus patients who did not
achieve such response(s). The observed improvements in
work productivity and SF-36 PCS scores were more
closely related to ACR20 response, whereas improvement
in the SF-36 MCS score was more closely related to im-
provement in both arthritis and skin symptoms of PsA
(Figure 2).
Physical function, HRQOL, and productivity through
week 104. Early improvements in physical function and
HRQOL, as well as the lessened impact of disease on
productivity, were maintained and/or enhanced through
week 104 among patients in the golimumab groups (Table
2). In addition, patients who were randomized to placebo
and crossed over to golimumab 50 mg at week 16 (early
escape) or week 24 (crossover) achieved mean improve-
ments in HAQ DI, SF-36 PCS, SF-36 MCS, and impact of
disease on productivity scores at weeks 52 and 104 that
were similar to those observed in patients who started
Figure 1. Proportions of patients achieving a clinically meaningful change from baseline in Health Assessment Questionnaire (HAQ)
disability index (DI; 0.30) and 36-item Short Form health survey physical component summary (PCS; 5) and mental component
summary (MCS; 5) scores at weeks 14, 24, 52, and 104. At weeks 52 and 104, all patients initially randomized to placebo were receiving
golimumab (50 or 100 mg), and some patients initially randomized to golimumab 50 mg were receiving golimumab 100 mg.
Figure 2. Relationships between improvements in physical component summary (PCS) and mental component
summary (MCS) scores of the 36-item Short Form health survey (SF-36) and the impact of disease on productivity and
achievement () or nonachievement () of an American College of Rheumatology 20% improvement criteria
(ACR20) and Psoriasis Area and Severity Index 75% improvement (PASI75) response criteria at week 24.
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golimumab therapy at week 0 (Table 2). Likewise, the
proportions of patients with clinically meaningful im-
provements in HAQ DI and SF-36 PCS and MCS scores
were generally similar among the 3 treatment groups at
weeks 52 and 104, although patients who received pla-
cebo followed by golimumab appeared to experience less
improvement in the SF-36 MCS score at week 104 than
patients who received golimumab at the study outset
(Figure 1).
At week 52, after adjusting for age, sex, and HAQ DI or
SF-36 PCS or MCS scores at baseline, and when compared
with patients who did not achieve a DAS28-CRP score
2.6, greater proportions of patients who achieved a
DAS28-CRP score2.6 also had normal physical function,
i.e., a HAQ DI score 0.5 (78.8% versus 30.0%; OR 6.8,
P  0.0001), and normal (50) PCS (55.6% versus 12.6%;
OR 8.4, P  0.0001) and MCS (68.8% versus 52.1%; OR
2.0, P  0.01) scores. Comparable ﬁndings were observed
when these analyses were repeated with week 104 data
(Table 3). Likewise, productivity was improved to a greater
extent in patients who achieved a DAS28-CRP score 2.6
versus those who did not at both week 52 (median im-
provement of 82.5% versus 33.3%; P  0.001) and week
104 (median improvement of 82.1% versus 29.4%; P 
0.001).
DISCUSSION
In the GO-REVEAL trial, a phase III, multicenter, random-
ized, placebo-controlled study, the safety and efﬁcacy of
subcutaneous golimumab (50 or 100 mg) was assessed in
405 adult patients with PsA. Golimumab-treated patients
with PsA had signiﬁcant improvements in measures of
joint and skin disease versus placebo (11), and treatment
beneﬁts were maintained through week 104 (13,14). The
golimumab safety proﬁle was acceptable during this same
time period and was similar to that of other anti-TNF
agents (11,13,14). Owing to the substantial impact that PsA
can have on patient physical function and HRQOL (2,3),
which in turn affect work ability (productivity), the GO-
REVEAL trial also included measurements of patient phys-
ical function, HRQOL, and productivity. In addition to
providing further evidence of the clinical efﬁcacy of goli-
mumab treatment, such assessments provide information
on whether this efﬁcacy is truly “meaningful” from patient
and societal perspectives.
At baseline, patients enrolled in the GO-REVEAL trial
had SF-36 PCS and MCS scores that were lower than those
in the general population of the US, indicating impairment
in both the physical and psychosocial aspects of HRQOL.
The effects of golimumab on physical function as mea-
sured by the HAQ DI, HRQOL as measured by the SF-36
PCS and MCS scores, and the impact of disease on pro-
ductivity appear to be substantial through week 104 of
the GO-REVEAL trial. Through week 24 (the placebo-
controlled period), patients treated with golimumab 50 or
100 mg had signiﬁcantly greater improvements in physical
function, HRQOL, and the impact of disease on productiv-
ity when compared with patients who received placebo;
these improvements with golimumab treatment are gen-
erally comparable in magnitude to those observed with
inﬂiximab therapy for PsA (25). Improvements at week 24
were maintained in the golimumab groups at weeks 52 and
104, at which time improvements in physical function,
HRQOL, and productivity were similar among the 3 treat-
ment groups, including patients randomized to placebo
treatment who had a 4- to 6-month delay in initiating
golimumab.
At week 24, improvements in arthritis symptoms (per
the DAS28-CRP score) were signiﬁcantly correlated with
improvements in physical function and the physical com-
ponent of HRQOL, and a decrease in the impact of disease
on productivity. Overall, patients achieving an ACR20
and/or PASI75 response exhibited greater improvement in
productivity and in the SF-36 PCS and MCS scores than
did patients not achieving an ACR20 or PASI75 response.
Although improvements in work productivity and the
SF-36 PCS score more closely paralleled an ACR20 re-
sponse, improvement in the SF-36 MCS score was more in
line with achievement of both an ACR20 and PASI75
response, which would not be unexpected given the addi-
tional psychosocial burden that accompanies the skin
component of PsA (26). Compared with improvement in
the SF-36 PCS score, improvement in the SF-36 MCS score
was numerically smaller. These ﬁndings may be related to
the greater impairment in physical function (SF-36 PCS)
than mental function (SF-36 MCS) at baseline (means of
31.9–33.0 versus 45.0–47.6), which is consistent with
ﬁndings generally observed in inﬂammatory rheumatic
diseases (26), and would make it difﬁcult to discern im-
provements over time. Another possibility is that changes
in psychologically-based measures, such as the SF-36 MCS
Table 3. Physical function and health-related quality of life by achievement of a DAS28-CRP score <2.6 in all treatment
groups combined*
Week 52 Week 104
N No Yes OR† P N No Yes OR† P
HAQ DI score 0.5 348 57 (30.0) 126 (78.8) 6.8  0.0001 328 55 (34.2) 127 (75.1) 4.9  0.0001
SF-36 PCS score 50 347 24 (12.6) 89 (55.6) 8.4  0.0001 328 11 (6.8) 79 (46.7) 9.9  0.0001
SF-36 MCS score 50 347 99 (52.1) 110 (68.8) 2.0  0.01 328 81 (50.0) 120 (71.0) 2.5  0.001
* Values are the number (percentage) unless otherwise indicated. DAS28-CRP  28-joint Disease Activity Score using the C-reactive protein level;
OR  odds ratio; HAQ  Health Assessment Questionnaire; DI  disability index; SF-36  36-item Short Form health survey; PCS  physical
component summary; MCS  mental component summary.
† ORs were estimated based on the logistic regression model by adjusting for age, sex, and baseline value (HAQ DI or SF-36 PCS or MCS scores).
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score, may lag behind changes observed in the physical
aspects of PsA. Although greater improvements from base-
line to week 24 in enthesitis and dactylitis scores were
observed in golimumab- versus placebo-treated patients
(data not shown), these improvements exhibited only
weak correlations with physical function, HRQOL, and
work productivity. The reasons for the weak correlations
are not entirely clear, but may relate to some extent to the
methods currently used to assess these areas of involve-
ment. At present, there is an ongoing debate concerning
the optimal means by which dactylitis and enthesitis
should be assessed. At the time this study was designed,
the analyses chosen and included in this study repre-
sented the consensus of those involved in the study de-
sign. However, it is possible that more sensitive methods
of evaluation (e.g., ultrasound examination) may allow
more detailed quantiﬁcation of change; therefore, these
outcomes might correlate more strongly with outcomes
such as HRQOL, physical function, and productivity.
Furthermore, greater proportions of patients who
achieved a DAS28-CRP score 2.6 at week 52 and week
104 achieved normal physical function and normal
HRQOL when compared with patients who did not. Like-
wise, productivity was improved to a greater extent at both
week 52 and week 104 in patients who achieved a DAS28-
CRP score 2.6 at these time points.
Assessment of productivity in patients and the impact of
treatment is an important and practical way to measure
disability from individual and societal perspectives. We
evaluated the impact of PsA on daily productivity at work,
school, or home in the previous 4 weeks using a self-
reported 10-cm VAS. Although this speciﬁc instrument
has not undergone rigorous measurement property testing,
it has been used in previously conducted clinical trials
of biologic agents in ankylosing spondylitis (27) and PsA
(28), and has been determined to be signiﬁcantly corre-
lated with physical function and disease activity, as well
as sensitive to change in physical function and disease
activity (27). In addition, the use of a similar tool, i.e., a
0–100 VAS, where 0  not affected at all and 100 
completely affected, in measuring the impact of RA on
work performance has demonstrated acceptable reliability
and validity (29). Therefore, it is likely that the signiﬁcant
and sustained improvement we observed in patient pro-
ductivity with golimumab therapy will result in decreased
indirect costs over the long term. Although our evaluations
extended through week 104 of the trial, ﬁndings are lim-
ited by the lack of a placebo control group beyond week
24.
In conclusion, monthly subcutaneous injections of goli-
mumab 50 or 100 mg signiﬁcantly improved physical
function and HRQOL and lessened the impact of disease
on productivity in patients with active PsA. These ﬁndings
indicate that treatment with golimumab signiﬁcantly re-
duces the overall disease burden placed on patients with
PsA.
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